Abstract 5527: A novel fully human anti-TIGIT and PVRIG bispecific antibody that elicits potent anti-tumor efficacy in pre-clinical studies

提吉特 抗体 流式细胞术 癌症研究 T细胞 免疫系统 单克隆抗体 免疫学 化学 生物
作者
Shuang Dai,Weifeng Huang,Yuan Zhou,Shaogang Peng,Jiayi Si,Chao Wang,Xiaoniu Miao,Yingda Xu,Joanne Sun,Xiaolin Liu,Andy Tsun,Tianhang Zhai
出处
期刊:Cancer Research [American Association for Cancer Research]
卷期号:82 (12_Supplement): 5527-5527
标识
DOI:10.1158/1538-7445.am2022-5527
摘要

Abstract Background: TIGIT (T-cell immunoglobulin and ITIM domain), which is primarily expressed on activated and 'exhausted' T and NK cells, is one of the promising 'next generation' immune checkpoint molecules. Engagement of TIGIT to its ligands (i.e., PVR and PVRL2) leads to inhibitory signaling in T cells, promoting functional exhaustion of tumor-infiltrating T lymphocytes. Anti-TIGIT monoclonal antibodies have shown clinical benefit when combined with anti-PD-L1 agents in NSCLC. However, the single-agent efficacy of anti-TIGIT therapies have been limited. PVRIG (PVR-related immunoglobulin domain containing), which is another coinhibitory receptor of the DNAM/TIGIT/CD96 nectin family, binds with high affinity to PVRL2 and suppresses T-cell function, and shows nonredundant inhibitory effects alongside the TIGIT/PVR/PVRL2 axis. Here, we report a fully-human anti-TIGIT × PVRIG bispecific antibody (anti-TIGIT × PVRIG biAb), which blocks both the PVRIG/PVRL2 and TIGIT/PVR/PVRL2 pathways, that maintains the efficacy of the combination of the two mono-agents. The anti-TIGIT × PVRIG biAb is also highly efficacious when combined with PD1/PD-L1 inhibitors in mouse tumor models. Methods: An anti-TIGIT × PVRIG biAb was generated through the fusing of a fully-human IgG targeting TIGIT with a wild type G1-Fc to a fully-human scFv at the c-terminus targeting PVRIG. Binding affinity and specificity analyses were studied by flow cytometry and biolayer interferometry. The co-binding of the anti-TIGIT × PVRIG biAb to TIGIT and PVRIG was detected by ELISA. The immunomodulatory functions of the anti-TIGIT × PVRIG biAb were evaluated using a luciferase reporter cell assay in vitro and human PBMC-based tumor models in vivo. Results: The anti-TIGIT × PVRIG biAb binds with high affinity to the extracellular domain of human TIGIT/PVRIG and can bind to TIGIT and PVRIG simultaneously. In a competition assay, the anti-TIGIT × PVRIG biAb efficiently blocked the interaction between TIGIT and PVR/PVRRL2, and PVRIG with PVRL2. In a luciferase reporter cell system, the anti-TIGIT × PVRIG biAb induced high levels of luciferase activity compared with the anti-TIGIT or anti-PVRIG mAbs alone. In vivo, the anti-TIGIT × PVRIG biAb demonstrated stronger anti-tumor efficacy than the anti-TIGIT and anti-PVRIG mAbs as monotherapies or combined with anti-PD-1 mAb. Conclusion: Our anti-TIGIT × PVRIG biAb, a fully human bispecific antibody, either alone or in combination with anti-PD-1 mAb promotes immune cell activation both in vitro and in vivo, supporting its clinical development for the treatment of human cancers. The molecule is currently under GLP-toxicity evaluation in NHP, and a first-in-human study is expected to begin in 2022. Citation Format: Shuang Dai, Weifeng Huang, Zhijun Yuan, Shaogang Peng, Jiayi Si, Chao Wang, Xiaoniu Miao, Yingda Xu, Joanne Sun, Xiaolin Liu, Andy Tsun, Tianhang Zhai. A novel fully human anti-TIGIT and PVRIG bispecific antibody that elicits potent anti-tumor efficacy in pre-clinical studies [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 5527.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
神内小大夫完成签到,获得积分10
刚刚
1秒前
shinysparrow应助科研大佬采纳,获得10
2秒前
2秒前
可爱的函函应助wenwen采纳,获得10
4秒前
4秒前
无花果应助神内小大夫采纳,获得10
4秒前
头秃科研人完成签到,获得积分10
4秒前
陪伴发布了新的文献求助10
6秒前
vgh发布了新的文献求助10
7秒前
8秒前
Satoru发布了新的文献求助10
9秒前
11秒前
紫金大萝卜应助Lx采纳,获得20
12秒前
深情安青应助Tioner采纳,获得10
12秒前
13秒前
15秒前
Satoru完成签到,获得积分10
15秒前
19秒前
wenwen发布了新的文献求助10
20秒前
安谢发布了新的文献求助10
21秒前
Owen应助沙发采纳,获得10
22秒前
beihai完成签到,获得积分10
22秒前
nqbscxttdh完成签到 ,获得积分10
23秒前
曾医生完成签到,获得积分10
23秒前
luca发布了新的文献求助10
24秒前
25秒前
香蕉觅云应助dan1029采纳,获得10
26秒前
沉思猫发布了新的文献求助10
26秒前
李健应助dan1029采纳,获得10
26秒前
自觉的依波完成签到 ,获得积分10
28秒前
英俊的铭应助一只桶采纳,获得10
28秒前
30秒前
31秒前
31秒前
32秒前
浩凡完成签到,获得积分10
33秒前
36秒前
36秒前
FMK发布了新的文献求助10
36秒前
高分求助中
Teaching Social and Emotional Learning in Physical Education 900
Plesiosaur extinction cycles; events that mark the beginning, middle and end of the Cretaceous 800
Recherches Ethnographiques sue les Yao dans la Chine du Sud 500
Two-sample Mendelian randomization analysis reveals causal relationships between blood lipids and venous thromboembolism 500
Chinese-English Translation Lexicon Version 3.0 500
[Lambert-Eaton syndrome without calcium channel autoantibodies] 440
Wisdom, Gods and Literature Studies in Assyriology in Honour of W. G. Lambert 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2389597
求助须知:如何正确求助?哪些是违规求助? 2095638
关于积分的说明 5278257
捐赠科研通 1822775
什么是DOI,文献DOI怎么找? 909128
版权声明 559537
科研通“疑难数据库(出版商)”最低求助积分说明 485825